Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group

Stephanie SasseInternal Medicine I, German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany; Correspondence[email protected]

Magdalena AlramInternal Medicine I, German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany;

Horst MüllerInternal Medicine I, German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany;

Lenka SmardováUniversity Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;

Bernd MetznerDepartment of Hematology and Oncology, Hospital of Oldenburg, Oldenburg, Germany;

Hartmut DoehnerClinic III for Internal Medicine, University Hospital of Ulm, Ulm, Germany;

Thomas FischerDepartment of Hematology and Oncology, University Hospital of Magdeburg, Magdeburg, Germany;

Dietger W. NiederwieserDepartment of Hematology and Oncology, University Hospital of Leipzig, Leipzig, Germany;

Norbert SchmitzDepartment of Hematology, Oncology, Asklepios Clinic St. Georg, Hamburg, Germany;

Kerstin Schäfer-EckartDepartment of Oncology/Hematology, Klinikum Nuernberg Nord, Nuernberg, Germany;

John M. M. RaemaekersDepartment of Hematology, Radboud University Medical Center, Nijmegen, Netherlands;

Oliver SchmalzClinic I for Internal Medicine, Helios Clinic Wuppertal, Wuppertal, Germany

Bastian V. TresckowInternal Medicine I, German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany;

Andreas EngertInternal Medicine I, German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany;

Peter BorchmannInternal Medicine I, German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany;

References